<!doctype html>
<html class="docs-version-current" lang="en" dir="ltr">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width,initial-scale=1">
<meta name="generator" content="Docusaurus v2.0.0-beta.6">
<link rel="search" type="application/opensearchdescription+xml" title="Genomenal" href="/ngsw-docs-en/opensearch.xml"><title data-react-helmet="true">Variant Pathogenicity | Genomenal</title><meta data-react-helmet="true" name="twitter:card" content="summary_large_image"><meta data-react-helmet="true" property="og:url" content="https://genomenal.com/ngsw-docs-en/results/main/snvs-indels/pathogenicity"><meta data-react-helmet="true" name="docsearch:language" content="en"><meta data-react-helmet="true" name="docsearch:version" content="current"><meta data-react-helmet="true" name="docsearch:docusaurus_tag" content="docs-default-current"><meta data-react-helmet="true" property="og:title" content="Variant Pathogenicity | Genomenal"><meta data-react-helmet="true" name="description" content="The variant pathogenicity can be determined either manually (by user), by the ACMG classification, or by"><meta data-react-helmet="true" property="og:description" content="The variant pathogenicity can be determined either manually (by user), by the ACMG classification, or by"><link data-react-helmet="true" rel="shortcut icon" href="/ngsw-docs-en/img/favicon.png"><link data-react-helmet="true" rel="canonical" href="https://genomenal.com/ngsw-docs-en/results/main/snvs-indels/pathogenicity"><link data-react-helmet="true" rel="alternate" href="https://genomenal.com/ngsw-docs-en/results/main/snvs-indels/pathogenicity" hreflang="en"><link data-react-helmet="true" rel="alternate" href="https://genomenal.com/ngsw-docs-en/results/main/snvs-indels/pathogenicity" hreflang="x-default"><link data-react-helmet="true" rel="preconnect" href="https://DZAOFCP7KJ-dsn.algolia.net" crossorigin="anonymous"><link rel="stylesheet" href="/ngsw-docs-en/assets/css/styles.ce916e14.css">
<link rel="preload" href="/ngsw-docs-en/assets/js/runtime~main.58663b83.js" as="script">
<link rel="preload" href="/ngsw-docs-en/assets/js/main.9097e47c.js" as="script">
</head>
<body>
<script>!function(){function t(t){document.documentElement.setAttribute("data-theme",t)}var e=function(){var t=null;try{t=localStorage.getItem("theme")}catch(t){}return t}();t(null!==e?e:"light")}()</script><div id="__docusaurus">
<div><a href="#" class="skipToContent_1oUP">Skip to main content</a></div><nav class="navbar navbar--fixed-top"><div class="navbar__inner"><div class="navbar__items"><button aria-label="Navigation bar toggle" class="navbar__toggle clean-btn" type="button" tabindex="0"><svg width="30" height="30" viewBox="0 0 30 30" aria-hidden="true"><path stroke="currentColor" stroke-linecap="round" stroke-miterlimit="10" stroke-width="2" d="M4 7h22M4 15h22M4 23h22"></path></svg></button><a href="https://genomenal.com" target="_blank" rel="noopener noreferrer" class="navbar__brand"><img src="/ngsw-docs-en/img/app-logo.svg" alt="Genomenal Logo" class="themedImage_1VuW themedImage--light_3UqQ navbar__logo"><img src="/ngsw-docs-en/img/app-logo-white.svg" alt="Genomenal Logo" class="themedImage_1VuW themedImage--dark_hz6m navbar__logo"><b class="navbar__title"></b></a></div><div class="navbar__items navbar__items--right"><div class="react-toggle toggle_3Zt9 react-toggle--disabled"><div class="react-toggle-track" role="button" tabindex="-1"><div class="react-toggle-track-check"><span class="toggle_71bT">🌜</span></div><div class="react-toggle-track-x"><span class="toggle_71bT">🌞</span></div><div class="react-toggle-thumb"></div></div><input type="checkbox" class="react-toggle-screenreader-only" aria-label="Switch between dark and light mode"></div><div class="searchBox_1Doo"><button type="button" class="DocSearch DocSearch-Button" aria-label="Search"><span class="DocSearch-Button-Container"><svg width="20" height="20" class="DocSearch-Search-Icon" viewBox="0 0 20 20"><path d="M14.386 14.386l4.0877 4.0877-4.0877-4.0877c-2.9418 2.9419-7.7115 2.9419-10.6533 0-2.9419-2.9418-2.9419-7.7115 0-10.6533 2.9418-2.9419 7.7115-2.9419 10.6533 0 2.9419 2.9418 2.9419 7.7115 0 10.6533z" stroke="currentColor" fill="none" fill-rule="evenodd" stroke-linecap="round" stroke-linejoin="round"></path></svg><span class="DocSearch-Button-Placeholder">Search</span></span><span class="DocSearch-Button-Keys"></span></button></div></div></div><div role="presentation" class="navbar-sidebar__backdrop"></div></nav><div class="main-wrapper docs-wrapper docs-doc-page"><div class="docPage_31aa"><button class="clean-btn backToTopButton_35hR" type="button"><svg viewBox="0 0 24 24" width="28"><path d="M7.41 15.41L12 10.83l4.59 4.58L18 14l-6-6-6 6z" fill="currentColor"></path></svg></button><aside class="docSidebarContainer_3Kbt"><div class="sidebar_15mo"><nav class="menu thin-scrollbar menu_Bmed menuWithAnnouncementBar_2WvA"><ul class="theme-doc-sidebar-menu menu__list"><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" href="/ngsw-docs-en/">Introduction</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" href="/ngsw-docs-en/log_in">Login to the System</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" href="/ngsw-docs-en/overview">Get to Know Genomenal</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" href="/ngsw-docs-en/quick-start-for-tumor-analysis">Quick Start for Tumor Analysis</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" href="/ngsw-docs-en/quick-start-for-prenatal-genetic-testing">Quick Start for Prenatal Genetic Testing</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" href="/ngsw-docs-en/data-for-analysis">Samples for Analysis</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" href="/ngsw-docs-en/add-patient">Adding Patient</a></li><li class="theme-doc-sidebar-item-category menu__list-item menu__list-item--collapsed"><a class="menu__link menu__link--sublist" href="#">Uploading Samples</a></li><li class="theme-doc-sidebar-item-category menu__list-item"><a class="menu__link menu__link--sublist menu__link--active" href="#">Analysis Results</a><ul style="display:block;overflow:visible;height:auto" class="menu__list"><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/results">Sample Page</a></li><li class="theme-doc-sidebar-item-category menu__list-item"><a class="menu__link menu__link--sublist menu__link--active" href="#" tabindex="0">Main</a><ul style="display:block;overflow:visible;height:auto" class="menu__list"><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/main/main">Main</a></li><li class="theme-doc-sidebar-item-category menu__list-item"><a class="menu__link menu__link--sublist menu__link--active" href="#" tabindex="0">SNVs/Indels</a><ul style="display:block;overflow:visible;height:auto" class="menu__list"><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/main/snvs-indels/snvs-indels">SNVs/Indels</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/main/snvs-indels/variant-viewer">SNV Viewer</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/main/snvs-indels/snv-details-panel">Variant Details Panel</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/main/snvs-indels/basic-filtering">Basic Filtering of Variants</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/main/snvs-indels/advanced-filtering">Advanced Filtering of Variants</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/main/snvs-indels/edit-table-columns">Edit Table Columns</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/main/snvs-indels/snv-details-page">Variant Details Page</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link menu__link--active" aria-current="page" tabindex="0" href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity">Variant Pathogenicity</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/main/snvs-indels/onco-relevance">Variant Onco Relevance</a></li></ul></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/main/structural-variations">Structural Variations</a></li><li class="theme-doc-sidebar-item-category menu__list-item menu__list-item--collapsed"><a class="menu__link menu__link--sublist" href="#" tabindex="0">Copy Number Variations</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/main/alignments">Alignments</a></li></ul></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/variants-by-phenotypes">ClinVar Phenotypes Report</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/onco-genetic-testing-report">Onco-Genetic Testing Report</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/acmg-sf-report">ACMG Secondary Findings Report</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/glioma-report">Glioma Report</a></li><li class="theme-doc-sidebar-item-category menu__list-item menu__list-item--collapsed"><a class="menu__link menu__link--sublist" href="#" tabindex="0">CNV Report</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/bioinformatic-report">Bioinformatic Report</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/coverage-analysis">Coverage Analysis</a></li><li class="theme-doc-sidebar-item-category menu__list-item menu__list-item--collapsed"><a class="menu__link menu__link--sublist" href="#" tabindex="0">Workflow Details</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" tabindex="0" href="/ngsw-docs-en/results/parameters">Parameters</a></li></ul></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" href="/ngsw-docs-en/runs">Runs</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" href="/ngsw-docs-en/group-analysis">Group Analysis</a></li><li class="theme-doc-sidebar-item-link menu__list-item"><a class="menu__link" href="/ngsw-docs-en/cohorts">Cohorts</a></li><li class="theme-doc-sidebar-item-category menu__list-item menu__list-item--collapsed"><a class="menu__link menu__link--sublist" href="#">Settings</a></li><li class="theme-doc-sidebar-item-category menu__list-item menu__list-item--collapsed"><a class="menu__link menu__link--sublist" href="#">Examples of Samples</a></li></ul></nav></div></aside><main class="docMainContainer_3ufF"><div class="container padding-top--md padding-bottom--lg"><div class="row"><div class="col docItemCol_3FnS"><div class="docItemContainer_33ec"><article><div class="tocCollapsible_1PrD theme-doc-toc-mobile tocMobile_3Hoh"><button type="button" class="clean-btn tocCollapsibleButton_2O1e">On this page</button></div><div class="theme-doc-markdown markdown"><header><h1>Variant Pathogenicity</h1></header><p>The variant pathogenicity can be determined either manually (by user), by the ACMG classification, or by
the pathogenicity database uploaded as a custom annotation. Information about the variant pathogenicity is located
in &quot;Pathogenicity&quot; column in SNV Viewer. If the pathogenicity was not determined, then the column value
will be <img src="data:image/png;base64,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" width="40"> (not applicable).</p><h2><a aria-hidden="true" tabindex="-1" class="anchor anchor__h2 anchorWithStickyNavbar_31ik" id="manually-determined-pathogenicity"></a>Manually determined pathogenicity<a class="hash-link" href="#manually-determined-pathogenicity" title="Direct link to heading">#</a></h2><p>To determine the variant pathogenicity by yourself, click on the pathogenicity
button <img src="data:image/png;base64,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" width="42"> in the variant row
(&quot;<strong>Pathogenicity</strong>&quot; column) and select the required option in the dialog:</p><p align="center"><img src="/ngsw-docs-en/assets/images/pathogenicity_list-d99c72226827958fd68da168724baf0a.png" width="300"></p><div class="admonition admonition-info alert alert--info"><div class="admonition-heading"><h5><span class="admonition-icon"><svg xmlns="http://www.w3.org/2000/svg" width="14" height="16" viewBox="0 0 14 16"><path fill-rule="evenodd" d="M7 2.3c3.14 0 5.7 2.56 5.7 5.7s-2.56 5.7-5.7 5.7A5.71 5.71 0 0 1 1.3 8c0-3.14 2.56-5.7 5.7-5.7zM7 1C3.14 1 0 4.14 0 8s3.14 7 7 7 7-3.14 7-7-3.14-7-7-7zm1 3H6v5h2V4zm0 6H6v2h2v-2z"></path></svg></span>info</h5></div><div class="admonition-content"><p>If a variant has been determined as Pathogenic or Likely pathogenic, it is
automatically <a href="/ngsw-docs-en/results/main/snvs-indels/variant-viewer#include-to-report">included to report</a>
(if pathogenicity has been <a href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity#confirm-pathogenicity">confirmed</a>).</p></div></div><p>Pathogenicity can be overdetermined in the same dialog.</p><p>You can also determine pathogenicity in &quot;<strong>ACMG Classification</strong>&quot; tab using the ACMG criteria, as
described <a href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity#define-pathogenicity-on-acmg-tab">here</a>.</p><div class="admonition admonition-info alert alert--info"><div class="admonition-heading"><h5><span class="admonition-icon"><svg xmlns="http://www.w3.org/2000/svg" width="14" height="16" viewBox="0 0 14 16"><path fill-rule="evenodd" d="M7 2.3c3.14 0 5.7 2.56 5.7 5.7s-2.56 5.7-5.7 5.7A5.71 5.71 0 0 1 1.3 8c0-3.14 2.56-5.7 5.7-5.7zM7 1C3.14 1 0 4.14 0 8s3.14 7 7 7 7-3.14 7-7-3.14-7-7-7zm1 3H6v5h2V4zm0 6H6v2h2v-2z"></path></svg></span>info</h5></div><div class="admonition-content"><p>The variant pathogenicity class determined manually is stored in the system and will automatically be
determined for the same variant in samples annotated later
with <a href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity#confirm-pathogenicity">a warning to confirm the pathogenicity</a>.</p></div></div><h2><a aria-hidden="true" tabindex="-1" class="anchor anchor__h2 anchorWithStickyNavbar_31ik" id="acmg-classification"></a>Variant ACMG Classification<a class="hash-link" href="#acmg-classification" title="Direct link to heading">#</a></h2><p>&quot;ACMG Classification&quot; is a tab on <a href="/ngsw-docs-en/results/main/snvs-indels/snv-details-page">the variant details page</a>
that provides the variant interpretation criteria developed
by <a href="https://www.acmg.net/" target="_blank" rel="noopener noreferrer">American College of Medical Genetics and Genomics (ACMG)</a>. To get to the tab,
click on the pathogenicity button <img src="data:image/png;base64,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" width="42"> in
the variant row (&quot;<strong>Pathogenicity</strong>&quot; column) and click on the &quot;ACMG Classification&quot; option in the dialog:</p><p align="center"><img src="/ngsw-docs-en/assets/images/acmg_on_dialog-57189e424ba378f51a2f4a337f35f669.png" width="300"></p><p>You will see &quot;ACMG classification&quot; tab on <a href="/ngsw-docs-en/results/main/snvs-indels/snv-details-page">the variant details page</a>
(you can also access the tab from other tabs on the page).</p><p>On the left side of the tab, there is a <strong>navigation bar for ACMG criteria</strong> grouped by category.
When you click on the name of a certain criteria group, it will be displayed on the right side of the page,
and when you click on a certain criterion, you will see the corresponding group criterion.
Criteria that are undefined for the variant are shown in <span style="background-color:#999AAB;border-radius:2px;color:#fff;padding:0.2rem">grey</span>;
criteria that does not meet the variant - in <span style="background-color:#141E29;border-radius:2px;color:#fff;padding:0.2rem">black</span>;
benign criteria that meet the variant - in <span style="background-color:#219653;border-radius:2px;color:#fff;padding:0.2rem">green</span>;
and pathogenic criteria that meet the variant - in <span style="background-color:#E95726;border-radius:2px;color:#fff;padding:0.2rem">orange</span>.</p><p align="center"><img src="/ngsw-docs-en/assets/images/criteria_review-381c1a5e417c5f1964e29cab4765a4d9.png" height="600"></p><p>On the right side of the tab, there is a detailed information about each criterion by group.
For each criterion, there are:</p><ol><li><strong>Criterion&#x27;s code and significance</strong> presented as an icon. The icon color matches the color on
the navigation bar on the left: <span style="background-color:#999AAB;border-radius:2px;color:#fff;padding:0.2rem">grey</span> means that the criterion is
undefined for the variant; <span style="background-color:#141E29;border-radius:2px;color:#fff;padding:0.2rem">black</span> - the criterion doesn&#x27;t meet the
variant;<br><span style="background-color:#219653;border-radius:2px;color:#fff;padding:0.2rem">green</span> - the benign criterion that meets the
variant; <span style="background-color:#E95726;border-radius:2px;color:#fff;padding:0.2rem">orange</span> - the pathogenic criterion that meets the variant.</li><li><strong>Decision</strong>: Automatic (the criterion state is determined automatically), UNDEFINED (the criterion state
is undefined) or MANUALLY CHANGED (the criterion state was determined by the user; to return to automatic
determination of the criterion&#x27;s state and significance,
click on <img src="data:image/png;base64,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" width="25">);</li><li><strong>Criterion state</strong>: UNDEFINED - the criterion is not defined for the variant; UNMET - the criterion
does not meet the variant; MET - the criterion meets the variant. The selected state is indicated in blue.
The state of the criterion can be changed by clicking on the button of the required state.</li></ol><p align="center"><img src="data:image/png;base64,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" width="360"></p><ol start="4"><li>The criterion can be expanded by clicking on <img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABkAAAAgCAYAAADnnNMGAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAEnQAABJ0Ad5mH3gAAACiSURBVEhL7c0xCoBADERRD2FtK3b2HsHO1vvYWHnU9QIrA9sJ2SQT1sYPA2nC63KDvkdSusvFJSLrtodAIjLOSwhURfphoiEVwkJqhIFMiBcyIx7IhWAWyI1gWohCMA1EI1gNCkEwCQpDjvMqX+9CEAlANFIDEIVoAORGtAByIRYAmRErgEyIB0BqxAsgFcIAqIqwABKRCACJSFQ/YqoBkvMDA7/ytPgTXKkAAAAASUVORK5CYII=" width="15">.
Here you can add <strong>a comment</strong> to the criterion and change <strong>the criterion significance level</strong>: supporting,
moderate (if if there is no &quot;Stand alone&quot; option), strong; very strong (if if there is no &quot;Stand alone&quot; option);
stand alone (if there are no options &quot;Moderate&quot; and &quot;Very strong&quot;; independent criterion of very high significance).
There will also be &quot;Literature&quot; section with a list of publications associated with the criterion, if such
associations were
added on <a href="/ngsw-docs-en/results/main/snvs-indels/snv-details-page#associate-article-with-acmg-criterion">&quot;Literature&quot; tab</a>.</li></ol><h3><a aria-hidden="true" tabindex="-1" class="anchor anchor__h3 anchorWithStickyNavbar_31ik" id="population-data"></a>1. Population data<a class="hash-link" href="#population-data" title="Direct link to heading">#</a></h3><p>At the top of the section, there are:</p><ul><li>GnomAD AF is the total allele frequency
in <a href="https://gnomad.broadinstitute.org/news/2020-10-gnomad-v3-1/" target="_blank" rel="noopener noreferrer">gnomAD v3</a> database;</li><li>ExAC AF is the total allele frequency in <a href="http://exac.broadinstitute.org/" target="_blank" rel="noopener noreferrer">ExAC</a> database;</li><li>1000G AF is the total allele frequency in <a href="https://www.internationalgenome.org/" target="_blank" rel="noopener noreferrer">the 1000 Genomes Project</a>;</li><li>Max AF is the maximum allele frequency among all frequencies in different populations according to different
databases;</li><li>Min AF is the minimum allele frequency among all frequencies in different populations according to different
databases.</li></ul><h4><a aria-hidden="true" tabindex="-1" class="anchor anchor__h4 anchorWithStickyNavbar_31ik" id="population-data-criteria"></a>Population data criteria<a class="hash-link" href="#population-data-criteria" title="Direct link to heading">#</a></h4><table><tr><td>Criterion</td><td>Criterion significance level</td><td>Criterion pathogenicity</td><td>Description of the variant that meets the criterion</td></tr><tr><td><b>Pathogenic Moderate 2 (PM2)</b></td><td>Moderate</td><td>Pathogenic</td><td><b>Absent</b> from controls (or <b>at extremely low frequency</b> if recessive: ≤0.01% for autosomal dominant diseases or ≤0.5% for autosomal recessive diseases) in <a href="https://gnomad.broadinstitute.org/" target="_blank" rel="noopener noreferrer">gnomAD</a>, <a href="https://www.internationalgenome.org/" target="_blank" rel="noopener noreferrer">1000 Genomes</a> or <a href="http://exac.broadinstitute.org/" target="_blank" rel="noopener noreferrer">ExAC</a>. Must be covered to a sufficient read depth/quality (&gt;100) in database.</td></tr><tr><td><b>Stand-alone evidence of benign impact 1 (BA1)</b></td><td>Very strong; independent criterion</td><td>Benign</td><td>The population <b>allele frequency is above 5%</b> in <a href="https://gnomad.broadinstitute.org/" target="_blank" rel="noopener noreferrer">gnomAD</a>, <a href="https://www.internationalgenome.org/" target="_blank" rel="noopener noreferrer">1000 Genomes</a>, or <a href="http://exac.broadinstitute.org/" target="_blank" rel="noopener noreferrer">ExAC</a> and the variant is not on <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188666/table/T1/?report=objectonly" target="_blank" rel="noopener noreferrer">the exception list by ClinGen SVI</a>.</td></tr><tr><td><b>Strong evidence of benign 1 (BS1)</b></td><td>Strong</td><td>Benign</td><td><b>Allele frequency is above 1%</b> and is greater than expected for disorder:<br>1. Variants known to be pathogenic for <i>dominant</i> disorders should have allele frequencies in the general population <i>below the disease incidence</i>.<br>2. Variant known to be pathogenic for <i>recessive</i> disorders should have heterozygous frequencies <i>consistent with their disease incidence</i>.<br>- For an autosomal dominant disorder with high penetrance it is acceptable to use this criterion as stand-alone evidence to classify a variant as likely benign.<br>- Be cautious using this code based on a low number of alleles in gnomAD if the disease is late onset or has variable penetrance/expressivity.<br>- To avoid duplication, the criterion is applied as UNMET if the variant meets the BA1 or PM2 criteria.</td></tr><tr><td><b>Strong evidence of benign 2 (BS2)</b></td><td>Strong</td><td>Benign</td><td>Observed <b>in a healthy adult individual</b> for a (1) recessive (homozygous), (2) dominant (heterozygous), or (3) X-linked (hemizygous) <b>disorder with full penetrance expected at an early age</b>.<br>- Use the criterion if it is reasonable to believe that individuals with the variant in large population databases are truly unaffected. The evidence can be accessed from gnomAD, the literature, or in-house data. For example, gnomAD shows the age distribution of heterozygous or homozygous variant carriers.<br>- Be cautious using this criterion based on a low numbers if the disease is late-onset or has variable penetrance/expressivity.</td></tr></table><h3><a aria-hidden="true" tabindex="-1" class="anchor anchor__h3 anchorWithStickyNavbar_31ik" id="odds-ratio"></a>2. Odds ratio<a class="hash-link" href="#odds-ratio" title="Direct link to heading">#</a></h3><h4><a aria-hidden="true" tabindex="-1" class="anchor anchor__h4 anchorWithStickyNavbar_31ik" id="odds-ratio-criteria"></a>Odds ratio criterion<a class="hash-link" href="#odds-ratio-criteria" title="Direct link to heading">#</a></h4><table><tr><td>Criterion</td><td>Criterion significance level</td><td>Criterion pathogenicity</td><td>Description of the variant that meets the criterion</td><td>Additional options</td></tr><tr><td valign="top"><b>Pathogenic Strong 4 (PS4)</b></td><td valign="top">Strong</td><td valign="top">Pathogenic</td><td><b>The prevalence of the variant in affected individuals is significantly higher than in controls</b>. Relative risk or odds ratio, as obtained from case-control studies, is &gt;5.0, and the confidence interval around the estimate does not include 1.0.<br>- Case-control study data is rarely available and do not reach statistical significance for very rare variants and rare diseases, therefore use the criterion:<br>1. <i>at moderate level</i> if the same variant has been previously identified in multiple (two or more) unrelated affected individuals and has not been reported in gnomAD (or at extremely low frequency if autosomal recessive);<br>2. <i>at supporting level</i> if the same variant has been previously identified in one unrelated affected individual and has not been reported in gnomAD (or at extremely low frequency if autosomal recessive);<br>3. <i>at supporting level</i> if the same variant has been previously identified in multiple unrelated individuals but is not absent in controls.<br>- The patient phenotype must be consistent with the known disease spectrum.<br>- In practice this is most applicable to autosomal dominant disorders (for autosomal recessive disorders use <a href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity#cis-trans-criteria">PM3</a>).<br>- Both PS4 and <a href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity#population-data-criteria">PM2</a> can be used together.</td><td valign="top">To open a variant in <a href="https://www.ebi.ac.uk/gwas/" target="_blank" rel="noopener noreferrer">GWAS Catalog</a> for human genome-wide associations, expand the criterion description by clicking on <img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABkAAAAgCAYAAADnnNMGAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAEnQAABJ0Ad5mH3gAAACiSURBVEhL7c0xCoBADERRD2FtK3b2HsHO1vvYWHnU9QIrA9sJ2SQT1sYPA2nC63KDvkdSusvFJSLrtodAIjLOSwhURfphoiEVwkJqhIFMiBcyIx7IhWAWyI1gWohCMA1EI1gNCkEwCQpDjvMqX+9CEAlANFIDEIVoAORGtAByIRYAmRErgEyIB0BqxAsgFcIAqIqwABKRCACJSFQ/YqoBkvMDA7/ytPgTXKkAAAAASUVORK5CYII=" width="15">, and then click on <img src="/ngsw-docs-en/assets/images/search_in_gwas-ab502ff65f6bf39b3f6f957443ff1600.png" width="160">.</td></tr></table><h3><a aria-hidden="true" tabindex="-1" class="anchor anchor__h3 anchorWithStickyNavbar_31ik" id="uniq-pheno"></a>3. Uniq Pheno<a class="hash-link" href="#uniq-pheno" title="Direct link to heading">#</a></h3><h4><a aria-hidden="true" tabindex="-1" class="anchor anchor__h4 anchorWithStickyNavbar_31ik" id="uniq-pheno-criteria"></a>Uniq Pheno criterion<a class="hash-link" href="#uniq-pheno-criteria" title="Direct link to heading">#</a></h4><table><tr><td>Criterion</td><td>Criterion significance level</td><td>Criterion pathogenicity</td><td>Description of the variant that meets the criterion</td></tr><tr><td valign="top"><b>Supporting evidence of pathogenicity 4 (PP4)</b></td><td valign="top">Supporting</td><td valign="top">Pathogenic</td><td><b>Patient’s phenotype or family history is highly specific for a disease</b> with a single genetic etiology.<br>Before using the criterion, it is essential to make sure that:<br>1. all the known genes associated with the disorder have been analysed using a highly sensitive method appropriate for the reported types of variants;<br>2. variants in these known genes explain the majority of cases with that clinical diagnosis.</td></tr></table><h3><a aria-hidden="true" tabindex="-1" class="anchor anchor__h3 anchorWithStickyNavbar_31ik" id="cosegregation"></a>4. Cosegregation<a class="hash-link" href="#cosegregation" title="Direct link to heading">#</a></h3><p>At the top of the section, you can calculate <strong>the logarithm of the odds (LOD) score</strong> for a certain type
of segregation. LOD scores calculated in different families with the same variant can be added to assign
a final score. The final LOD score can then be used to determine the criterion significance level.
To calculate LOD score, do the following:</p><ol><li>Select segregation type: dominant/X-linked or recessive;</li><li>Enter the values of the number of affected segregations and unaffected segregations (if the recessive
segregation was chosen) (natural numbers);</li><li>Click outside the input box.</li></ol><p>The LOD score for dominant/X-linked segregation is calculated by the formula:</p><p align="center"><img src="/ngsw-docs-en/assets/images/lod_dominant-fe1f5d3a832c7a2bfd0e93db978bdb3e.png" width="450"></p><p>The LOD score for recessive segregation is calculated by the formula:</p><p align="center"><img src="/ngsw-docs-en/assets/images/lod_recessive-03b8e62f1d22bfa8ab3308b2fdad16f3.png" width="420"></p><h4><a aria-hidden="true" tabindex="-1" class="anchor anchor__h4 anchorWithStickyNavbar_31ik" id="cosegregation-criteria"></a>Cosegregation criteria<a class="hash-link" href="#cosegregation-criteria" title="Direct link to heading">#</a></h4><table><tr><td>Criterion</td><td>Criterion significance level</td><td>Criterion pathogenicity</td><td>Description of the variant that meets the criterion</td></tr><tr><td><b>Supporting evidence of pathogenicity 1 (PP1)</b></td><td>Supporting</td><td>Pathogenic</td><td>Located <b>in a gene definitively known to cause the disease</b> and that has <b>a co-segregation with this disease</b> in multiple affected family members.<br>- Before using the criterion, determine the segregation of a variant with disease phenotypes in pedigrees with affected patients. Use the criterion with an appropriate significance level if <i>a variant was found to co-segregate with multiple affected family members</i>. Use BS4 if there is a lack of segregation of a variant with affected members.<br>- Based on the recommendations from ClinGen <a href="https://clinicalgenome.org/working-groups/clinical-domain/hearing-loss/" target="_blank" rel="noopener noreferrer">The Hearing Loss Working Group</a>, use the criterion:<br>1. at supporting level if LOD = 0.6;<br>2. at moderate level if LOD = 1.2;<br>3. at strong level if LOD = 1.5.</td></tr><tr><td><b>Strong evidence of benign 4 (BS4)</b></td><td>Strong</td><td>Benign</td><td>Located in a gene that has <b>lack of segregation with the disease</b> in affected family members.<br>- Before using the criterion, determine the segregation of a variant with disease phenotypes in pedigrees with affected patients. Use the criterion if there is <i>a lack of segregation of a variant with affected members</i>. Use PP1 with an appropriate significance level if a variant was found to co-segregate with multiple affected family members.</td></tr></table><h3><a aria-hidden="true" tabindex="-1" class="anchor anchor__h3 anchorWithStickyNavbar_31ik" id="de-novo-variants"></a>5. <em>De novo</em> Variants<a class="hash-link" href="#de-novo-variants" title="Direct link to heading">#</a></h3><p><a href="https://clinicalgenome.org/working-groups/sequence-variant-interpretation/" target="_blank" rel="noopener noreferrer">The Sequence Variant Interpretation (SVI) Working Group</a>
proposes <a href="https://clinicalgenome.org/site/assets/files/3461/svi_proposal_for_de_novo_criteria_v1_1.pdf" target="_blank" rel="noopener noreferrer">a point-based system</a>
to determine the strength of <em>de novo</em> evidence (PS2 and PM6 criteria) based upon three parameters:</p><ul><li>choose PS2 if <em>de novo</em> status confirmed and PM6 if not;</li><li>phenotypic consistency;</li><li>number of <em>de novo</em> observations.</li></ul><h4><a aria-hidden="true" tabindex="-1" class="anchor anchor__h4 anchorWithStickyNavbar_31ik" id="de-novo-variants-criteria"></a><em>De novo</em> Variants criteria<a class="hash-link" href="#de-novo-variants-criteria" title="Direct link to heading">#</a></h4><table><tr><td>Criterion</td><td>Criterion significance level</td><td>Criterion pathogenicity</td><td>Description of the variant that meets the criterion</td></tr><tr><td><b>Pathogenic Strong 2 (PS2)</b></td><td>Strong</td><td>Pathogenic</td><td><b><i>De novo</i> in a patient with the disease</b> and no family history. <b>Maternity and paternity confirmation</b> is required.</td></tr><tr><td><b>Pathogenic Moderate 6 (PM6)</b></td><td>Moderate</td><td>Pathogenic</td><td><b>Assumed <i>de novo</i></b>, but without confirmation of paternity and maternity.</td></tr></table><p>For <em>De novo</em> Variants criteria, you can add <strong><em>additional unrelated patients (probands) with the same phenotype</em></strong>:</p><ol><li>Expand the criterion description by clicking on <img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABkAAAAgCAYAAADnnNMGAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAEnQAABJ0Ad5mH3gAAACiSURBVEhL7c0xCoBADERRD2FtK3b2HsHO1vvYWHnU9QIrA9sJ2SQT1sYPA2nC63KDvkdSusvFJSLrtodAIjLOSwhURfphoiEVwkJqhIFMiBcyIx7IhWAWyI1gWohCMA1EI1gNCkEwCQpDjvMqX+9CEAlANFIDEIVoAORGtAByIRYAmRErgEyIB0BqxAsgFcIAqIqwABKRCACJSFQ/YqoBkvMDA7/ytPgTXKkAAAAASUVORK5CYII=" width="15">;</li><li>For Proband 1 (the name can be changed by clicking on the current one and entering a new one), click on
the search box and select the appropriate consistency between phenotype and gene;</li></ol><p align="center"><img src="/ngsw-docs-en/assets/images/proband-74946e8fc7f02af22fd012554829c620.png" width="500"></p><ol start="3"><li>To add another patient, click on <img src="/ngsw-docs-en/assets/images/add_proband-6b62763a01c54af4737332c73eb39cd3.png" width="150">.</li></ol><p>After adding all patients, click on the button that appears to apply the criterion significance level
corresponding to the phenotypes of the patients:</p><p align="center"><img src="/ngsw-docs-en/assets/images/change_strength-85c78adc35b247c44c9426500ff008f8.png" width="700"></p><p>After that, the criterion state will change to MET (the criterion meets the variant) and the criterion
significance level will correspond to the phenotypes of the added patients.</p><p>To delete a patient, click on <img src="data:image/png;base64,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" width="20">.</p><h3><a aria-hidden="true" tabindex="-1" class="anchor anchor__h3 anchorWithStickyNavbar_31ik" id="cis-trans"></a>6. Cis-trans<a class="hash-link" href="#cis-trans" title="Direct link to heading">#</a></h3><h4><a aria-hidden="true" tabindex="-1" class="anchor anchor__h4 anchorWithStickyNavbar_31ik" id="cis-trans-criteria"></a>Cis-trans criteria<a class="hash-link" href="#cis-trans-criteria" title="Direct link to heading">#</a></h4><table><tr><td>Criterion</td><td>Criterion significance level</td><td>Criterion pathogenicity</td><td>Description of the variant that meets the criterion</td><td>Additional options</td></tr><tr><td valign="top"><b>Pathogenic Moderate 3 (PM3)</b></td><td valign="top">Moderate</td><td valign="top">Pathogenic</td><td valign="top">Detected <b>in trans with a pathogenic variant</b> for recessive disorders.<br>- <a href="https://clinicalgenome.org/working-groups/sequence-variant-interpretation/" target="_blank" rel="noopener noreferrer">The Sequence Variant Interpretation (SVI) Working Group</a> proposes <a href="https://www.clinicalgenome.org/site/assets/files/3717/svi_proposal_for_pm3_criterion_-_version_1.pdf" target="_blank" rel="noopener noreferrer">a point-based system</a> to determine the criterion significance level for variants in trans observations based upon variant phasing and classification of the variant occurring on the other allele.<br>- SVI recommends a revision to the criterion definition: &quot;for recessive disorders, detected in trans with a pathogenic <b><i>or likely pathogenic variant in an affected patient</i></b>&quot;.</td><td>You can add additional unrelated patients (probands) with the same variant:<br>1. Expand the criterion description by clicking on <img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABkAAAAgCAYAAADnnNMGAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAEnQAABJ0Ad5mH3gAAACiSURBVEhL7c0xCoBADERRD2FtK3b2HsHO1vvYWHnU9QIrA9sJ2SQT1sYPA2nC63KDvkdSusvFJSLrtodAIjLOSwhURfphoiEVwkJqhIFMiBcyIx7IhWAWyI1gWohCMA1EI1gNCkEwCQpDjvMqX+9CEAlANFIDEIVoAORGtAByIRYAmRErgEyIB0BqxAsgFcIAqIqwABKRCACJSFQ/YqoBkvMDA7/ytPgTXKkAAAAASUVORK5CYII=" width="15">;<br>2. For Proband 1 (the name can be changed by clicking on the current one and entering a new one), click on the search box and select the variant phase;<br>3. In the activated search box, select the variant classification;<br>4. To add another patient, click on <img src="/ngsw-docs-en/assets/images/add_proband-6b62763a01c54af4737332c73eb39cd3.png" width="150">.<br>After adding all patients, click on the button that appears to apply the criterion significance level corresponding to the added patients. After that, the criterion state will change to MET (the criterion meets the variant) and the criterion significance level will correspond to the variant classification in added patients.<br>To delete a patient, click on <img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAACsAAAAoCAYAAABnyQNuAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAEnQAABJ0Ad5mH3gAAAHrSURBVFhH7dNPSsNAFMfxnMZz6CHUhXgBdS3uxBtYEe/QPx7B1pXgVvAA/qFtalFr2kjStOP8qgMhvs68mSRgpA++Gzvz8kESL4oiUZVW2LLy4jgWVala2Ol0KqrS/8QGV03y73my3WnEhnc3oru5tsjfWxfv9VPynE1Apndy0V6SJELX8HhHdLfk4lQjCabOchq3JTSzD2DqbDYjNrtY5QKmoCrqfDYj9vX8kFyObMA6KJ5B3clmxEa9B+Hvb5APQRywDord1B0qIxZF/UcxkEt7cjnVqF4j7yFAqTsIO6k7y/Jms5ngFCvwtnwQ0Uej9uvOpN0izyLsyp43xcai2P8G9+XDqNLgSadFnkEuUGSFRRxwGVDkzedzYdvUfxIvGvCycIfax80JixbgAz4YZ6k9NjljERdcBBTlwiIOmLrnUm5sqPmYVIH86Ki7tuXCcqCqoHFG7rDJGWsDVeUFO2HDziWJQXh/de9w0HQHW2NNUJwxfXSuYCssB6oqA8zGhtd8qKpoMAvrAlUVCfaEYaL7W+HLpVRDieBMMnhenKV2oE/5z+CMEft2sks+gAtVowNzdxmxeZZnRwfmjBE7lu9UeqkrVA0FHl0c/fyqHyMWy/FO4XUAvIhx3WnE/qVZYcuaFbasqRBWiC+N36QcPfFWQQAAAABJRU5ErkJggg==" width="20">.</td></tr><tr><td valign="top"><b>Supporting evidence of benign impact 2 (BP2)</b></td><td valign="top">Supporting</td><td valign="top">Benign</td><td valign="top">Observed either <b>in trans</b> with a (likely) pathogenic variant for a fully penetrant <b>dominant</b> disorder, or <b>in cis</b> with a (likely) pathogenic variant for a fully penetrant disorder in any inheritance pattern.</td><td></td></tr></table><h3><a aria-hidden="true" tabindex="-1" class="anchor anchor__h3 anchorWithStickyNavbar_31ik" id="in-vitro-or-functional-studies"></a>7. <em>In vitro</em> or functional studies<a class="hash-link" href="#in-vitro-or-functional-studies" title="Direct link to heading">#</a></h3><p>Functional studies (<em>in vitro</em> or <em>in vivo</em>), considered when applying this section criteria,
should be validated, shown to be reproducible and robust in a clinical diagnostic laboratory setting.
Do not use <em>in silico</em> studies including protein modelling.</p><h4><a aria-hidden="true" tabindex="-1" class="anchor anchor__h4 anchorWithStickyNavbar_31ik" id="in-vitro-or-functional-studies-criteria"></a><em>In vitro</em> or functional studies criteria<a class="hash-link" href="#in-vitro-or-functional-studies-criteria" title="Direct link to heading">#</a></h4><table><tr><td>Criterion</td><td>Criterion significance level</td><td>Criterion pathogenicity</td><td>Description of the variant that meets the criterion</td></tr><tr><td><b>Pathogenic Strong 3 (PS3)</b></td><td>Strong</td><td>Pathogenic</td><td>Functional studies prove <b>a damaging effect</b> of the variant on the gene or gene product.<br>- The criterion significance level depends on strength of evidence (e.g. if only one reference is available, use the criterion with lower significance). Generally, <i>in vivo</i> studies provide stronger evidence than<i>in vitro</i> studies, and assays that rescue phenotypes provide stronger evidence than assays manipulating them.<br>- If studies provide support at the gene rather than variant level (e.g. biochemical analysis), this should be incorporated within the phenotypic specificity criterion <a href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity#uniq-pheno-criteria">PP4</a>.</td></tr><tr><td><b>Strong evidence of benign 3 (BS3)</b></td><td>Strong</td><td>Benign</td><td>Functional studies show <b>no effect</b> of the variant on the gene or gene product.</td></tr></table><h3><a aria-hidden="true" tabindex="-1" class="anchor anchor__h3 anchorWithStickyNavbar_31ik" id="protein-truncating-variants"></a>8. Protein-truncating variants<a class="hash-link" href="#protein-truncating-variants" title="Direct link to heading">#</a></h3><h4><a aria-hidden="true" tabindex="-1" class="anchor anchor__h4 anchorWithStickyNavbar_31ik" id="protein-truncating-variants-criteria"></a>Protein-truncating variants criteria<a class="hash-link" href="#protein-truncating-variants-criteria" title="Direct link to heading">#</a></h4><table><tr><td>Criterion</td><td>Criterion significance level</td><td>Criterion pathogenicity</td><td>Description of the variant that meets the criterion</td><td>Additional options</td></tr><tr><td valign="top"><b>Pathogenic Very Strong 1 (PVS1)</b></td><td valign="top">Very strong</td><td valign="top">Pathogenic</td><td valign="top"><b>LoF-variants</b> in a gene where loss of function (LoF) is a known mechanism of disease. LoF-variants are genetic variants predicted to severely disrupt protein-coding genes: nonsense, frameshift, canonical ±1 or ±2 splice sites, or initiation codon mutations, or single or multi-exon deletions/duplications.<br>- Do not use in combination with PM4 or <a href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity#in-silico-predictions-criteria">PP3</a>.</td><td valign="top">To use <b>a decision tree to determine the LoF effect of a variant</b> in the context of gene structure and molecular etiology, such as alternative splicing or nonsense-mediated mRNA decay (NMD),<br>click on <img src="/ngsw-docs-en/assets/images/pvs1_btn-f89378986c1336a0473b8737519cf039.png" width="146">. In the window that opens, step by step, select the characteristics that correspond to the variant. You can move between steps<br>using <img src="data:image/png;base64,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" width="140"> and <img src="data:image/png;base64,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" width="140">. As a result, you will get a decision: the state and strength (significance level) of the PVS1 criterion, depending on the specific LoF effect of the variant.</td></tr><tr><td valign="top"><b>Pathogenic Moderate 4 (PM4)</b></td><td valign="top">Moderate</td><td valign="top">Pathogenic</td><td valign="top"><b>An in-frame deletion/insertion or a stop-loss variant in a non-repeat region</b> of a gene that result in protein length changes.<br>- Do not use in combination with PVS1 or <a href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity#in-silico-predictions-criteria">PP3</a>.<br>- Use at supporting level for single amino acid in-frame deletion/insertion.</td><td></td></tr><tr><td valign="top"><b>Supporting evidence of benign impact 3 (BP3)</b></td><td valign="top">Supporting</td><td valign="top">Benign</td><td valign="top"><b>In-frame deletions/insertions in a repetitive region</b> of a gene. Without a known function.<br>- Do not use in combination with <a href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity#in-silico-predictions-criteria">BP4</a>.</td><td></td></tr></table><h3><a aria-hidden="true" tabindex="-1" class="anchor anchor__h3 anchorWithStickyNavbar_31ik" id="missense-variants"></a>9. Missense variants<a class="hash-link" href="#missense-variants" title="Direct link to heading">#</a></h3><h4><a aria-hidden="true" tabindex="-1" class="anchor anchor__h4 anchorWithStickyNavbar_31ik" id="missense-variants-criteria"></a>Missense variants criteria<a class="hash-link" href="#missense-variants-criteria" title="Direct link to heading">#</a></h4><table><tr><td>Criterion</td><td>Criterion significance level</td><td>Criterion pathogenicity</td><td>Description of the variant that meets the criterion</td></tr><tr><td><b>Pathogenic Strong 1 (PS1)</b></td><td>Strong</td><td>Pathogenic</td><td>Results in a substitution with <b>the same amino acid change</b> as <b>a previously established variant determined to be pathogenic</b> for this disease.<br>- Generally, used for missense variants, but may also be used at moderate level for initiation codon variants.<br>- Use at supporting level for different intronic change with the same or more severe splicing effect with reference to the predicted impact on the mRNA/protein.<br>- Beware of changes that impact splicing rather than at the amino acid/protein level.</td></tr><tr><td><b>Pathogenic Moderate 5 (PM5)</b></td><td>Moderate</td><td>Pathogenic</td><td>Novel missense change at an amino acid residue where a different <b>missense change determined to be pathogenic</b> has been seen before.<br>- Use at strong level if there are multiple observations of different pathogenic variants at the same residue.<br>- Use at supporting level if the variant is classified as likely pathogenic and there is only one case reported.<br>- Beware of changes that impact splicing rather than at the amino acid/protein level.</td></tr><tr><td><b>Pathogenic Moderate 1 (PM1)</b></td><td>Moderate</td><td>Pathogenic</td><td>Located in a mutational <b>hotspot</b> and/or critical and well-established <b>functional domain</b> (e.g. active site of an enzyme) <b>without benign variation</b>. A mutational hotspot can be considered if pathogenic variants are observed at a high frequency in one or several nearby residues. <i>In silico</i> protein modelling data can be included as supporting evidence.<br>- Use at strong level for very specific residues that are critical for protein structure or function.</td></tr><tr><td><b>Supporting evidence of pathogenicity 2 (PP2)</b></td><td>Supporting</td><td>Pathogenic</td><td>Missense variant in a gene that has <b>a low rate of benign missense variation</b> and where missense variants are <b>a common mechanism of disease</b>.<br>- Z scores ≥3.09 (marked amber in gnomAD) are significant, but it is important to consider constraint for the region encompassing the variant, not just across the entire gene. Z score is calculated by comparing the expected versus observed number of missense variants. The higher Z score, the higher the constraint or intolerance to variation.</td></tr><tr><td><b>Supporting evidence of benign impact 1 (BP1)</b></td><td>Supporting</td><td>Benign</td><td>Missense variant in a gene for which <b>primarily truncating variants</b> are known to cause disease.<br>- Use the criterion if all or nearly all (e.g., &gt;90%) of the disease-causing variants are truncations.</td></tr></table><h3><a aria-hidden="true" tabindex="-1" class="anchor anchor__h3 anchorWithStickyNavbar_31ik" id="in-silico-predictions"></a>10. <em>In silico</em> predictions<a class="hash-link" href="#in-silico-predictions" title="Direct link to heading">#</a></h3><p>At the top of the section, there are the results of predicting the effect of amino acid substitution
on protein function:</p><ul><li>DBNSFP DANN score is an effect prediction score made using <a href="https://cbcl.ics.uci.edu/public_data/DANN/" target="_blank" rel="noopener noreferrer">DANN</a>;</li><li>DBNSFP MetaLR prediction is an effect prediction value made using Meta LR;</li><li>DBNSFP GERP++ RS is an effect prediction score (rankscore) made
using <a href="http://mendel.stanford.edu/sidowlab/downloads/gerp/index.html" target="_blank" rel="noopener noreferrer">GERP++</a>.</li></ul><h4><a aria-hidden="true" tabindex="-1" class="anchor anchor__h4 anchorWithStickyNavbar_31ik" id="in-silico-predictions-criteria"></a><em>In silico</em> predictions criteria<a class="hash-link" href="#in-silico-predictions-criteria" title="Direct link to heading">#</a></h4><table><tr><td>Criterion</td><td>Criterion significance level</td><td>Criterion pathogenicity</td><td>Description of the variant that meets the criterion</td></tr><tr><td><b>Supporting evidence of pathogenicity 3 (PP3)</b></td><td>Supporting</td><td>Pathogenic</td><td>At least three lines of computational evidence support <b>a deleterious effect</b> on the gene or gene product (conservation, evolutionary, splicing impact, etc).<br>Caveat: as many <i>in silico</i> algorithms use the same or very similar input for their predictions, each algorithm <b>should not be counted as an independent criterion</b>.<br>- The criterion can be used only once in any evaluation of a variant.<br>- Do not use in combination with <a href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity#protein-truncating-variants-criteria">PVS1</a> or <a href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity#критерии-раздела-варианты-с-укорочением-белка">PM4</a>.<br>- Use PP3 if 2/3 tools predict deleterious effect, and use BP4 if 2/3 tools predict benign effect and there is no conservation or 3/3 tools predict benign effect.</td></tr><tr><td><b>Supporting evidence of benign impact 4 (BP4)</b></td><td>Supporting</td><td>Benign</td><td>At least three lines of computational evidence suggest <b>no impact</b> on gene or gene product (conservation, evolutionary, splicing impact, etc).<br>Caveat: As many <i>in silico</i> algorithms use the same or very similar input for their predictions, each algorithm <b>should not be counted as an independent criterion</b>. BP4 can be used only once in any evaluation of a variant.<br>- The criterion can be used only once in any evaluation of a variant.<br>- Do not use in combination with <a href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity#in-vitro-or-functional-studies-criteria">BS3</a>.<br>- Use PP3 if 2/3 tools predict deleterious effect, and use BP4 if 2/3 tools predict benign effect and there is no conservation or 3/3 tools predict benign effect.<br>- Use in combination with BP7 for synonymous variants affecting weakly conserved nucleotides which do not impact on splicing.</td></tr><tr><td><b>Supporting evidence of benign impact 7 (BP7)</b></td><td>Supporting</td><td>Benign</td><td>A synonymous (silent) variant for which splicing prediction algorithms predict <b>no impact to the splice consensus sequence</b> nor the creation of a new splice site, and <b>the nucleotide is not highly conserved</b>.<br>- Use in combination with BP4 for synonymous variants affecting weakly conserved nucleotides which do not impact on splicing.</td></tr></table><h3><a aria-hidden="true" tabindex="-1" class="anchor anchor__h3 anchorWithStickyNavbar_31ik" id="literature-data"></a>11. Literature data<a class="hash-link" href="#literature-data" title="Direct link to heading">#</a></h3><h4><a aria-hidden="true" tabindex="-1" class="anchor anchor__h4 anchorWithStickyNavbar_31ik" id="literature-data-criteria"></a>Literature data criteria<a class="hash-link" href="#literature-data-criteria" title="Direct link to heading">#</a></h4><table><tr><td>Criterion</td><td>Criterion significance level</td><td>Criterion pathogenicity</td><td>Description of the variant that meets the criterion</td></tr><tr><td><b>Supporting evidence of benign impact 5 (BP5)</b></td><td>Supporting</td><td>Benign</td><td>Found in a case with <b>an alternate molecular basis for disease</b> (basis that can explain the patient’s phenotype).<br>- Generally, the criterion is more applicable to dominant disorders with an obvious alternate mechanism.<br>- For recessive disorders, incidental carriers can harbor pathogenic variants unrelated to the disease phenotype.</td></tr><tr><td><b>Supporting evidence of pathogenicity 5 (PP5)</b></td><td>Supporting</td><td>Pathogenic</td><td>Reputable source recently reports variant as <b>pathogenic</b>, but the evidence is not available to the laboratory to perform an independent evaluation.<br>- The ClinGen <a href="https://clinicalgenome.org/working-groups/sequence-variant-interpretation/" target="_blank" rel="noopener noreferrer">Sequence Variant Interpretation (SVI) Working Group</a> (2018) <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709533/" target="_blank" rel="noopener noreferrer">recommends</a> not to use PP5 and BP6 criteria.</td></tr><tr><td><b>Supporting evidence of benign impact 6 (BP6)</b></td><td>Supporting</td><td>Benign</td><td>Reputable source recently reports variant as <b>benign</b> but the evidence is not available to the laboratory to perform an independent evaluation.<br>- The ClinGen <a href="https://clinicalgenome.org/working-groups/sequence-variant-interpretation/" target="_blank" rel="noopener noreferrer">Sequence Variant Interpretation (SVI) Working Group</a> (2018) <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709533/" target="_blank" rel="noopener noreferrer">recommends</a> not to use PP5 and BP6 criteria.</td></tr></table><h2><a aria-hidden="true" tabindex="-1" class="anchor anchor__h2 anchorWithStickyNavbar_31ik" id="define-pathogenicity-on-acmg-tab"></a>Determination of pathogenicity on &quot;ACMG Classification&quot; tab<a class="hash-link" href="#define-pathogenicity-on-acmg-tab" title="Direct link to heading">#</a></h2><ul><li>The first time you open &quot;ACMG Classification&quot; tab, the variant criteria status will be determined automatically.</li><li>You can change the state and significance level of the criteria and add comments to them.</li><li>To <strong><em>erase all results of variant interpretation</em></strong>,
click on <img src="data:image/png;base64,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" width="38">.</li><li>To <strong><em>reset to automatic variant interpretation</em></strong>,
click on <img src="data:image/png;base64,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" width="38">.
After automatic interpretation is restored,
<a href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity#confirm-pathogenicity">a warning to confirm the interpretation</a> will appear.</li></ul><p>As a result of combining the criteria, the variant is <strong><em>classified by pathogenicity</em></strong> (Benign, Likely benign,
Uncertain significance, Conflicting interpretations of pathogenicity, Likely pathogenic, Pathogenic)
and the interpretation result is set on the pathogenicity scale:</p><p align="center"><img src="/ngsw-docs-en/assets/images/acmg_scale-d3314ba388a6b9cbd08dd846d2f88631.png" width="500"></p><ul><li>To <strong><em>manually classify a variant by pathogenicity</em></strong>, click on the name or point with the value
on the pathogenicity scale:</li></ul><p align="center"><img src="/ngsw-docs-en/assets/images/scale_by_user-010c9f45334a97aa0379a7c60b8dc60d.png" width="500"></p><div class="admonition admonition-info alert alert--info"><div class="admonition-heading"><h5><span class="admonition-icon"><svg xmlns="http://www.w3.org/2000/svg" width="14" height="16" viewBox="0 0 14 16"><path fill-rule="evenodd" d="M7 2.3c3.14 0 5.7 2.56 5.7 5.7s-2.56 5.7-5.7 5.7A5.71 5.71 0 0 1 1.3 8c0-3.14 2.56-5.7 5.7-5.7zM7 1C3.14 1 0 4.14 0 8s3.14 7 7 7 7-3.14 7-7-3.14-7-7-7zm1 3H6v5h2V4zm0 6H6v2h2v-2z"></path></svg></span>info</h5></div><div class="admonition-content"><p>The variant pathogenicity class determined manually is stored in the system and will automatically be
determined for the same variant in samples annotated later
with <a href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity#confirm-pathogenicity">a warning to confirm the pathogenicity</a>.</p></div></div><div class="admonition admonition-info alert alert--info"><div class="admonition-heading"><h5><span class="admonition-icon"><svg xmlns="http://www.w3.org/2000/svg" width="14" height="16" viewBox="0 0 14 16"><path fill-rule="evenodd" d="M7 2.3c3.14 0 5.7 2.56 5.7 5.7s-2.56 5.7-5.7 5.7A5.71 5.71 0 0 1 1.3 8c0-3.14 2.56-5.7 5.7-5.7zM7 1C3.14 1 0 4.14 0 8s3.14 7 7 7 7-3.14 7-7-3.14-7-7-7zm1 3H6v5h2V4zm0 6H6v2h2v-2z"></path></svg></span>info</h5></div><div class="admonition-content"><p>If a variant has been determined as Pathogenic or Likely pathogenic, it is
automatically <a href="/ngsw-docs-en/results/main/snvs-indels/variant-viewer#include-to-report">included to report</a>
(if pathogenicity has been <a href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity#confirm-pathogenicity">confirmed</a>).</p></div></div><h2><a aria-hidden="true" tabindex="-1" class="anchor anchor__h2 anchorWithStickyNavbar_31ik" id="define-pathogenicity-by-base"></a>Determination of pathogenicity by pathogenicity base<a class="hash-link" href="#define-pathogenicity-by-base" title="Direct link to heading">#</a></h2><p>If you have uploaded a pathogenicity database into the system as
described <a href="/ngsw-docs-en/settings/custom-annotations#define-annotation-type">here</a>, the base will annotate sample variants.
Thus, if variants are presented in the base, their pathogenicity will correspond to the pathogenicity class in
the base (and marked as &quot;manually determined&quot;), but such a pathogenicity needs to
be <a href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity#confirm-pathogenicity">confirmed</a>.</p><h2><a aria-hidden="true" tabindex="-1" class="anchor anchor__h2 anchorWithStickyNavbar_31ik" id="defined-pathogenicity-in-vv"></a>Determined variant pathogenicity in SNV Viewer<a class="hash-link" href="#defined-pathogenicity-in-vv" title="Direct link to heading">#</a></h2><p>After completing the classification of the variant by pathogenicity (according to ACMG or manually)
or after annotating the variants by pathogenicity base, the pathogenicity button will change accordingly:</p><ul><li>Pathogenic variant: <img src="data:image/png;base64,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" width="40"></li><li>Likely pathogenic variant: <img src="data:image/png;base64,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" width="40"></li><li>Variant of uncertain significance: <img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAM8AAACACAYAAACsjz3mAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAEnQAABJ0Ad5mH3gAABJOSURBVHhe7Z35dxzFEcfzH/IgQCDc5iaEACHcVwgQwm0g3Ee4z3AEnIRTxpElG9uyZVtCNraRZcsCWSZGtgkmxB1/9r3htWprp2dme3ZnRlXvfX4Aq4+dre90d3V178+cmZlZITPxmJkVNBOPmVlBM/GYmRW0Sonn8OHDbm5uzk1OTrrx8XE3MjLihoeH3YoVK9zAwID7+OOPjUUA3zXfOd89PoAv4BP4Bj5SFeureI4cOeJmZ2fdxMRE60FpD9IwJPgKPoPv4EP9sr6IhzfI2NiYjSZG1+BD+BI+1WvrmXh4Q0xNTdkIY5QGvoWP9Wo06ol4mK8yh9U+sGTV6jVudPOE27J9yk1Oz7k9ew+42f3fu7kDP7pvDh0xFgF813znfPf4AL6AT+Abms9I8DV8rmwrVTwzMzNuaGhI/YAJgyuH3Kbxra2HZAIxQuAj+Ao+g+9oPpWA7+GDZVkp4jl06JAbHR1VP1DCho3jbufMPvUBGUZW8CF8SfOxBHwRn4xt0cUzPT3dMRAwsHy5G9uyvTUkaw/CMIqCT+Fb+Jjqe0d9Et+MaVHFQ/hQ6zhs/vwLt3f+B/WDG0Ys8DF8TfNBwEdjWRTxsHHFZpbW2bUjG1oLP+2DGkZZ4HP4nuaT+GqMzdauxXPw4MGO4WeiJNoHM4xegQ9qvonP4rvdWFfimZ+fd4ODg20dG1q12u2e/Vb9MIbRa/BFfFL6Kb6LDxe1wuJBtZpw1q3faCFno3Lgk/im9Fd8uOgIVEg8zBe1qRobWVrHDaMq4KPSb/HlImugQuLRggNsWmmdNYyqga9K/8Wn81pu8WjhaBtxjLqhjUB5w9i5xMMmk2yQeaTWOcOoOtoaKM9GambxkN4gMweIYFhwwKgr+K6MwuHjWVN5MotHy1WzcLRRd/Bh6df4ehbLJB4yU2UDtgFqNAVtIzVLNnYm8chjBaQ9aJ0wjLoiU3nw+ZAFxcOhIr9SsFw1o2ng09LPQwfqUsXDcVZ5ApSMVa1xw6g7Mhsb30870p0qHs6D+5VxVsKOFRhNBd+W54HQQCdLFY9MweGwkdaoYTQFfNz3eTTQyTqKh6t8/ErAToAaTQcfl37f6VqrjuLhLiy/As6Ja40ZRtOQdyKgBc1U8bBIktkEdlmHsVjA133fRwta4EAVD9eY+oW54kdrxDCaCj7vawBNSFPFIzOn7biBsdiQxxa0jGtVPDLKxiVzWgOG0VTweV8DWtStTTycqPMLgWVOG4sNfF7qQJ42bROPDFFzP7BWuWF0YnruoFs/ts198Mmge+zJZ91DjzzxE/w3/59/5++08lVB3o0tQ9Zt4pG5bGWfEh37Ypc748yz3DHHHKNy8sm/dCObervmoj3a1foDZy05232+fVotCyuG16nlEvh3rVxM7n/wYbVtuODCi9zknm/UckXYd/B/bv3mbe7hx55K/S41+HvKbd461apHq79fyNOmMtetTTz8CpdfoOyjB7P7D7tbb/+T+mATXnjlDbVsWdCe1o+EO+++383N/1ctC4tFPHuPPoOPPh1u1ae1k5dLLr3MfTq0rjIikkcV0IZvbeKRl3v0IljAMK49zISrr72+Z0M87dCe1g849thj3YfL00P3i0E8G8a3u19dfIlaf7dcefW1bmLHHrXdXiKDBvKSkDbxyEhbL44ffLHza3f+BReqDxJ6OXULTdnoJ/3VyiY0WTyMCm+++093woknqnXH4qSTT3Yfr1jd11FIHlOQEbc28cgjCL3IZ2MKdM/9D6oPMaFXU7fQlG3pQ48Gv9Cmiodp2lN/ebE1+mr1xgaBvr3sg74JSOa5oQ3f2sQj03J6FaZeuWbUHX/8CepDhCuvutZN7y136kb9tKO1D/SPfmplfZooHhz4tTff7ZlwEhDQwOBnap/KRoar0YZvbeLx/xi0Sstg58z+1oJRe4Dwi5NOcmtHy438UT/taO0D/aOfWlmfJoqHhXyWqRriuuJ3V7l3ln3YiqT6a1VGLp7f8LpNuSJzS5ac48a37VrQn14h9eBbZcQD7AFoDy/h2RdeVcvFgvq1dhPon1ZO0jTxTH213112+RVqXT5ETSd2dA7hSxjNEGWWwMNd9y5tiU+rp0ykHnyrlHhCb/5LL/+t2/X1vFq2W6iX+rV2IU/Qomni+dvfP0qdrjEiEUQoujbZs++Qu3fpQ2rdCf3Y7wOpB98qJZ5QmJg1B0O+VrZbqDdtzZUnXN4k8cx885274aZb1HoAUbEW6nZR//X+w27pg4+obSRkHfljIvXgW6XEA6FoV1kPMDRlfPWv76rlNJokHjIpyKjQ6gH2ZHbNxpkNbJ38yp173vlqO9CLoJFE6sG3yolndHyHO+XU09SHB2VM3UJTNha2LH61shpNEk/os7z7j3g+wuj16BPPqO1AKC2qDKQefKuceBi+b7n1j+rDg6zh4jyEwuT0h35pZTWaJB5GXK0OOOWUU1uZBlq5ogyu3tBxfcVLlZerVq4spB58q5x4gLeZ9vASeDt1O8dOCL3tIO/bddGIpwRn3r33QCsC98m/Vqt8OZ2t37GQevCtkuIh/eWcc89TvzDIut+ShdD+Ev0IpeNITDzNQerBt0qKJ5SuE3PqFpqy0Y+0DGqNxSIeIKlXK9cUpB58q6R4gMzltL2FLDlmIShPPVr9QPuhDGqNJoknbQ0ChLEJZ2tlm4DUg2+VFQ9z2wsvulj9woB/63b+G2qj6PSwSeIJhaoRFtsL/dj97wVSD75VVjyhhTxfGgtLrWxWKJ/2Vi0amGiSeLIcVuQZMoJ/9c1/1DrqjNSDb5UVD4TWI91M3UJTNtotms3QJPHAwOCa1O8hgXo5WdqkUUjqwbdKiye0eZnlYFonQgfwutnNbpp42OO67Y671Lo02P95/OnnWqdBi77cqoLUg2+VFg+kpeswXSiyoIdQQKKbw3dNEw9s37XX/fqSS9X60jjttNPd3fc90PrMZSX1lonUg2+VF0/oWHSRUHIoFN5tBm8TxQMEDy66+NdqnVlh34yzPEyJ6xClk3rwrfLiCWX1Fpm6haZs3YZfmyoemJz5t7vp97eq9eaFkf+S31zWyuCIlVwaG6kH3yovHuAcu/bwE/Ju1IVu66E9rVxWmiweYB3DtPf0M85Q6y/Cccf93P3htjvc5q07K7VOknrwrRbiCV2MGLpHzYe/4++1eiBvBrVG08WTwCG2Z557uRUg0NopAqPRNdfd4Ma37Vbb7DVSD77VQjyhvYY8+Wf8XVreHO3QnlY2K4tFPAns77x/dDTn7oK0IEweuHrq9bfe63vYW+rBt1qIB0JTraxTt7R6uone+Sw28fhw2pb71hjdEYDWfh7uvOf+zCd4y0DqwbfaiCe0yM8yYoRGsG72jXwWs3h8WLtwOvSNt5e19s1Y12j9CcFaqF8CknrwrTbiCYWXs5wyDOVpxUg2BROPDi+vdRu3tkLVeddJlMm7JREDqQffaiMeCKXrhA6tpR2yo95YxxxMPGF4SSEkRpUsIxI39AyvLefylzSkHnyrlXhCB9fSjkuHjnfHPGBn4skHkTUuEtH66tOP4w9SD77VSjyQdstNWpg5FO6OeSuPiSc/RNVIiUqL1nWTrFsUqQffaieetYGLETttcKZttMa+ytfEUwwExK/HaX1OKPvWWInUg2+1E0/oYkRt6haassX+/Z9+iycUVayqeGDLlzNuydnnqP2GGPtweZB68K124oG0TGtt6haasnWTQa0REs8rr7+tlotF6NceSO6Mtb6LTUj4vb74UOrBt1qKJ3QxorzdM+0SixjpOBLuMksLxeZJJypCKCRf9XsHqjTllHrwrZbiCU3DfOcIZWWnReiKsmN6X+qGbpHrrPIQSqR98OHH1XI+M/u+c9fdcJNaHsoUoImnZNL2bPz7xEKjVN4LDbNArlcobV+OjrEIrQkhy2cOTZ/KegGEXnYIGmFrZctA6sG32oonlOCZrGPS1kdljgCh+8640JzUFa1sN5CgmRbuzTNNTdsWiJUHKAmtTy1gEIFQug5vX44Op72Fi5xCzUrICQBHiDn1WT+2Ldhmnmlq6Kj69TfeHDVKyXdBGo7WVoKFqiOR9uVylPqRJ57peIS7rDdnQkjcCaw/Yqy5GMVCdwzk/cyMymlrN3jupdeiHRvgt0fTfrrRNkkjErq0MI0YlyaGWDM6kXr/QgLrox2759Q6QpAjRs4Xv9up1e2Td5FP3aFL8BHkk88839ULgHaWfbA8+JunsffjsiD14FutxZPly+1E0QsN80D9XMGktS/h7MuLr76Z+Sw/dZMTdvsdd6VOrRIQMWLW6kojFHBJIDetyBFqfsM0y2fg31nPaXWUidSDb7UWD4QyrTViZlCH4E2Z58IMMozZCOSnCj9bP94Kyyawhlu+co17/Kln3bnnXaCW18Dxiv70IWWYmmn1avDjvK+88U5rzact7JnikUVAxC/PydObb7mttNB4GlIPvtVePKGLETV6vUtd9M6zWJAv1s26JO8LQHLmWUtaKTdZhSIhCLJx4ku1b2Uj9eBb7cUDaeFojdjpOFnYNDF5dPF9kdqfMrlv6Z+j3CHNCyDLz8nHBuFw7kfrUy+QevCtEeIJXYzow9/14yfJYdvUrLvmuhvVfsWG6d9Lr70VLRIG3NlGeFprrwx42cT+2ca8SD341iaegYGBBX88d+BHtdIqEdqV9ikzrSQLRKVYf8S4HKMTrDtWj4wVWuOEoP9PP/ti4fsIssD07o4772mJVetDr8D3fS2gDd/axLNixYoFBWb3f69WXDVC+VwJ3V5oGAtC09yZENMJuYTw7ffej7JvFIIoGQ4eW0QEET7b8Hkpws8Lvu9rAW341iae4eHhBQX27D2gVlw1suzo8+9ZU1N6BaFpRqI80TMfnJdIFMcgYk7RssJaiOha0f4DozAvEkLvVRBNAr7vawFt+NYmnpGRkQUFJqeLbd4Z+WE6SXj6+ZffcHff+0Dr3A3zfh82ComevbPsw6POtqsvgulE0n9eBmRGcw+17D+fic/29HMvtcLuhOCrJBgffN/XAtrwrU084+PjCwps2T6lVmwYTQff97WANnxrE8/k5OSCAqOb453tN4w6ge/7WkAbvrWJZ25u4VC1avUatWLDaDr4vq8FtOFbm3gOHz68oECrUA3C1YYRExmmBrThW5t4MBlxs6CBsdiQwQIZacNU8UxMLJzrbRrvX3qEYfQDfN7XAJqQpopndnZ2QcHBleUdGjOMKoLP+xpAE9JU8Rw5cqQtTWfnzD61EcNoGvi67/toAU1IU8WDjY2NLahgw8ZxtSHDaBr4uu/7aEGzjuKRIWuoS56bYRRF5rOBDFEn1lE8mIy6jW3pb3q4YZQNPu77vBZlSyxVPFNTC9MTBpYvd3vnf1AbNYy6g2/j477Po4FOlioeFknyiMLmz79QGzaMuoNv+76O72uBgsRSxYPJXDeoyzEFw8iKPH4AMpdNWlA82NDQwpj32pENagcMo67g076P4/MhyySemZmZBRWDHVUwmoI8egD4fMgyiQcbHR1ta2D37LdqZwyjLuDD0q/x9SyWWTyHDh1qyzoYWrXaMq6N2oLv4sO+T+Pj+HoWyywebHp6ekFDsG79RrVjhlF18F3pz/h4VsslHkxmXIOdNjXqhjwlClrmdJrlFg8mLwkBO7Zg1AV53ADk5R5ZrJB4OFEnU3fARiCj6mgjDr4sT4lmsULiwQ4ePOgGBwfbOsI80oIIRtXAJ7U1Dj6MLxexwuLB5ufnVQERwbAwtlEV8EUZVQN8Fx8ual2JB0O12hQObCPV6DfaBijgs0VHnMS6Fg/GfFELIgBpD5YLZ/QafE6m3CTgq0XWONKiiCcxLYydQMaqHWcwygYfk9nRPnnD0WkWVTwYm0wyEyGBsxIcNrITqUZs8Cl8S57H+cn3jvpkng3QLBZdPBjpDVounA/nxO1SEaNb8CF554AEX8yacpPHShFPYmSmyuMMEq74YdOKS+YsxG2EwEfwFXwG39F8KgHfy5IdXdRKFU9iHCqSJ1I7wf3AbGQRJeEhsfBjSDZhLR74rvnO+e7xAXwBn5B3R3cCXwsdZIthPREPxnFWzoN3CmsbRrfgW/hY2tHpmNYz8fjGVT7chdUpsGAYWcGH8KVO10OVaX0RT2K8IbjGlPChjUhGVvAVfAbf6dUoo1lfxSONjSveIMxX+RUuNrN4UMxhbZRaPPBd853z3eMD+AI+gW/E2NyMZZUSj5lZnczEY2ZW0Ew8ZmYFzcRjZlbInPs/odr0McIg2KQAAAAASUVORK5CYII=" width="44"></li><li>Variant with conflicting interpretations of
pathogenicity: <img src="data:image/png;base64,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" width="45"></li><li>Likely benign variant: <img src="data:image/png;base64,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" width="40"></li><li>Benign variant: <img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAANEAAAB/CAYAAABxLCdxAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAEnQAABJ0Ad5mH3gAAA0ISURBVHhe7Z3fkxTVHcXzr8QXH3z0xfLBF8sXXygQRDcEEKHcVX6lQqwsEHbVIEtQWElYBIIGQ/ghYSOCuLiCS4GICKiAy7JmBakUCT8lD75oWTd1pqorPd85Pd3T3bdntvecqs+TdvfszPkwM7fvvfMzpyhKpkgiRckYSaQoGSOJFCVjWkqiG99/545cOe02nu13zx/Z4Nr2dbmHdyx097/xlLt30xPunr6p7ud9j4kSg9cYrzVec7z26AC6gE6gG+hIq6WpEv3w049uYOykW3Z0U+UJY0+qEBZ0BZ1Bd9ChZqcpEuFflMWDvZV/cdiTJERS0CF0CZ1qVgqTCP9ibP1iv95xhDfQLXSs6HenQiTC51l8xmV/uOXRtxe7RYNr3NpT29yuiwfc4W+PuzPXP3cjdy66sf9+7b4RpQavMV5rvOZ47dEBdAGdQDdYZyzoGjpXVLxKtHdkyD20vYP+oQEPvjXPLTmyrvJk4cljT6wQAegIuoLOoDusUwHoHjroO14kunz3mpt3sIf+YQEdh1a5/tEB+kQJkRR0CF1iHQtAF9FJX8ldol3Dg5EDBvdtaXMrjvVV3qrZEyJEWtApdAsdY91DJ9FNH8lVIgw7sj8AdA6td+dvnadPgBB5gY6ha6yDAB3NO7lIhBtguCnGHnTbvuWVL4jsDxbCF+gcusc72ZXrTdvMEl26fTVy2BqjKuwPFKIo0EHWTXQW3c0jmSS6cHPMPbCtdoTkkZ0L3MDlIfpHCVE06CI6aXuK7qLDWZNaIljMBJp1oFtD1aLlQCfRTdtXdDjrO1IqifB5kn2Eww0x9gcI0Sqgo7a36HKW70ipJGKDCLj5xR60EK0Gumr7i06nTcMSsWFsvQOJ8QZ7R0o7/N2QRLhZZS+Mz5nsQQrR6rDvSGluyCaWCNMm7EwEjHhoEEGMV9BdO2qHjjc6RSixRGwunIaxxXgHHba9RtcbSSKJMBPWXkg3UkVZYDdkG5n9nUgiu5wB0ynYgxFivGKnCKHzSRMrERY3hU8ONBdOlA102vY86cK+uhJhma1dkYoZsuxBCDHesbO/0f0kS83rSoT16uGTYq2GljOIsoJu2/VIcCAudSWyU3uw6IldXIiygI6HOw8H4hIpEbYgCp8MaEWqKDvouO193HZckRJhL6/wibCOnV1UiLJh92yAC/VCJcKXKTs7QZuKiIkCuh7uPlyoN8BAJcL2rOGTYGsidjEhyordjgtORIVKZGdqa5mDmGjY5RL1ZnhTieyoHDbLYxcSoqyg82EH6o3S1UiEFX7hg4FmaouJBjpvPYha/VojkR3axv7H7CJClB2793fUUHeNRHaunFatpuPg8QNu0qRJuTBt2jQ395m5bl77XLek89du/ZZe9+5H77hz/9J9O5/Y1a9Rc+lqJMKvkoUP1JKHdOQpUT3a57e7vYf2uJGbw/RxiPTYJRJwg6VGIrsJiQYV0lGURAEzZs5w7xzud2N3R+njEY1jBxeiNjOpkciOzGnZQzqKlijgpdUvuq/+fY4+JtEYdnlE1AhdjUR26YPmy6WjWRKBpV2dEikH7Dw6uMFSI5Gd7qPh7XQ0UyLQ/XKXG72l1y4LdpgbbrDUSGR/5l4/8ZiOOImWvbDUvdr3SmIwKjdz9kx6LsbkyZPdrgM76GMTyUD3wy7ADZYaicIHAXZyEU+cRPjv7Lg4hv9z3u15f7eb/fRset4wzy16VsPgGbE+sEgiT/iSKODi9QuuZ90qeu4wu9/bSY8XybA+sEgiT/iWCOBdaWl3Jz1/QNfKFW70tr4bpcX6wCKJPFGERODkyAk3e84seg3Q/twz+kiXAesDiyTyRFES4ebqH9avptcAbTPa3PHzR+mxIh7rA4sk8kRREoF/fLiXXgNglG7gxEF6nIjH+sAiiTxRpESDpw65qVMfo9cBeV5romF9YJFEnihSoo/OHnaPT3+cXgdyQTJ2nIjH+sAiiTxRpEQHjr5LrwH0nSgb1gcWSeSJIiXC+iJ2DaDRuWxYH1gkkSeKkujzK6ddx4IOeg2wau1K9887l+ixIh7rA4sk8kQREmF4+49/fo2eH2BF7OCn2i8wC9YHFknkCd8SQaC/9m9zU6ZMoecHK1/5vfv6zgg9XiTD+sAiiTzhUyLMm+t9fW3lHhA7N3h2YYc7e/k0PV4kx/rAIok8kbdEeEfBFB98fGv7xZP0nAGYvf3ppU/oeURjWB9YJJEn4iTC2iDs3hMHdvnBdxt2Dgs+2r22ubfyTsUek2gc6wOLJPJEnER5Mv3J6e7VDWvcmW8+o49FpMf6wCKJPFGURF0vr6gMc2sAwQ/WBxZJ5Iki34kAPsr9ZukS9+FnH2jbrByxPrBIIk8ULVEYyHT2sj7a5YH1gUUSeaKZEoGZs3+piac5YH1gkUSeiJNo7wd73JdXzzYE7vv0D/7dLX9xWaIRO4h07NwQfXwiGdYHFknkiTiJ8N/ZcUm5cO1cZTi73owFoJuu2bA+sEgiT/iWKOD9j9+rLHdg1whYt3GtJqGmxPrAIok8UZREYP/RfXU/3mlNUXqsDyySyBNFSoQh7c3bX6fXCdjyt830WFEf6wOLJPJEkRIBzFbAFCF2LdC54rdu5MZX9FgRjfWBRRJ5omiJ4rbOmjNvjjszdooeK6KxPrBIIk8ULRHA+iJ2LaDvRemwPrBIIk80Q6J619T+c+mwPrBIIk+0mkTAxzXLjvWBRRJ5ohmFfnP3VnotgH3psD8dO05EY31gkUSeKFoi/Cre715aTq8F8MPIJ4aP0WNFNNYHFknkiaIlwq4+9W64LvjVfHfh2pf0WBGN9YFFEnmiSIkwNw5z5Nh1AjD8rXVGjWN9YJFEnihKImxIgo1J2DUCMDJ38Fj+38EmAtYHFknkCZ8S4R3lk4sfu9W9PbGzuAF+NBm/qsfOJepjfWCRRJ6Ik6jRXw8HL/R0N7T7D8D/q3eh9FgfWCSRJ+IkKgrIp01M0mN9YJFEnmgFiXp6V7mRm8P08YlkWB9YaiS6p29q1UFj5MQinmZKhO9JfW/+qXLviD02kQx0P+wC3GCpkejeTU9UHThyRy9EGpolUfv8dm2blRPoftgFuMFSI9H9bzxVdeCZ6/qBqDQUKVGw5xyWikue/ED3wy7ADZYaiR7esbDqwMPfHqcXEPXxJRFG2zBCt7S70/X9ZUNlW6zR2/q04AN0P+wC3GCpkahtX1fVgbsuanhUTEzQ/bALcIOlRqLnj2yoOnDtqW30AkKUHXQ/7ALcYKmRaOPZ/qoDFw2uoRcQouyg+2EX4AZLjURHrpyuOvDRtxfTCwhRdtD9sAtwg6VGohvff1d1INAwt5ho2OFtADdYaiRC7AidBhfERMMOKkSNzCFUomVHN1WdYMmRdfRCQpQVdD7sAJyICpVoYOxk1QkefGsevZAQZQWdDzsAJ6JCJfrhpx9rpv/0jw7QiwlRNtD1cPfhApyICpUIWTzYW3WijkOr6AWFKBvoerj7cKFeIiWyQ91A8+hE2bHz5UDU0HaQSIkQO0q34lgfvbAQZQEdD3e+3qhckLoSbf1if9UJ79vS5s7f0lp9UU7QbXQ83Hk4EJe6EuHLlF0a0Tm0nj4AIcY76Ha46+h+vQGFIHUlQuxcOqDlEaJs2GUPIGqunE2sRMhD2zuqTt62bzl9IEKMV9DpcMfR+aRJJNHekaGqCwAtkRBlwS55AOh80iSSCJl3sKfmQgOXh+iDEmK8gA7bXqPrjSSxRJfvXquZxfDIzgWa4S3GLeguOhzuNDqOrjeSxBIhu4YHqy4IZh3opg9QiFYH3bV9RscbTUMSIXaGN9DqVzHesKtWQb2Z2vXSsESI3cwEaLmEGC/YZQ4gahOSJEklEVb42SlBQO9IotVh70DoctSq1SRJJRFy6fZV98C26jUXAJ8zNdggWg10kn0HQofR5SxJLRFy4eYYFQkjHhr+Fq0CumhH4QC6iw5nTSaJEFjMPtoB3ZAVzYbdSAXobNZ3oCCZJULweZINNgBMp9BcO1E06JydyvP/TnZl+g5kk4tEQdjwdwBmyGoZhfANOmZnY4dJO4xdL7lKhOBmlZ3ZEIC1Glj0pBWyIm/QKXTLrgcKQCfT3EhNktwlQjBtgs21C4N17Nr8RGQFHbJ7IljQxUan8jQSLxIFwUxYu4zCgq2JcPMLm+VpaFzEgY6gK+iM3dbKgu41Mhs7bbxKFASLm+wK2Siw/zFuiGFUBU8WviDirRpPnn76svzgNcZrjdccrz06gC6gE3Zv7CjQtaQL6vJIIRIhWGaL9epRw+FCZAXdQseSLOnOM4VJFA62IMJeXlEDEEIkBR1Cl+K2tfKZpkgUBP9iYHtWDDvqHUokBV1BZ9Cdot91WJoqkQ1ugOFfFHyexa+S4aYYnjB8xsW/OPgJdPakivKA1xivNV5zvPboALqATqAbed4kzSstJZGijMdIIkXJGEmkKJni3P8AbBUO0ylI83cAAAAASUVORK5CYII=" width="40"></li></ul><div class="admonition admonition-info alert alert--info"><div class="admonition-heading"><h5><span class="admonition-icon"><svg xmlns="http://www.w3.org/2000/svg" width="14" height="16" viewBox="0 0 14 16"><path fill-rule="evenodd" d="M7 2.3c3.14 0 5.7 2.56 5.7 5.7s-2.56 5.7-5.7 5.7A5.71 5.71 0 0 1 1.3 8c0-3.14 2.56-5.7 5.7-5.7zM7 1C3.14 1 0 4.14 0 8s3.14 7 7 7 7-3.14 7-7-3.14-7-7-7zm1 3H6v5h2V4zm0 6H6v2h2v-2z"></path></svg></span>info</h5></div><div class="admonition-content"><p>If a variant has been determined as Pathogenic or Likely pathogenic, it is
automatically <a href="/ngsw-docs-en/results/main/snvs-indels/variant-viewer#include-to-report">included to report</a>
(if pathogenicity has been <a href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity#confirm-pathogenicity">confirmed</a>).</p></div></div><p>The way of determining the variant pathogenicity (&quot;by ACMG&quot; or &quot;manually determined&quot;) can be found in the
tooltip by hovering over the pathogenicity button.</p><p>Variants can be <strong><em>sorted</em></strong> from pathogenic to benign by clicking on &quot;Pathogenicity&quot; column name once,
and from benign to pathogenic by clicking on the column name twice.</p><p>Variants can be <strong><em>filtered</em></strong> by pathogenicity:</p><ul><li><a href="/ngsw-docs-en/results/main/snvs-indels/advanced-filtering#multiselect-filters">&quot;Pathogenicity&quot; filter</a> in advanced filtering mode;</li><li>an additional filter &quot;Pathogenicity&quot; in basic filtering mode
(can be added on <a href="/ngsw-docs-en/settings/profile#basic-mode-filters">&quot;Profile&quot; page</a>).</li></ul><p>The result of the classification of a variant by pathogenicity can be <strong><em>cleared</em></strong> by clicking on the
pathogenicity button in the variant row and selecting &quot;Clear&quot; option in the dialog:</p><p align="center"><img src="/ngsw-docs-en/assets/images/clear_on_dialog-3a4ec4265703ea4bb39ad5773490e96d.png" width="300"></p><h2><a aria-hidden="true" tabindex="-1" class="anchor anchor__h2 anchorWithStickyNavbar_31ik" id="confirm-pathogenicity"></a>Confirmation of the variant pathogenicity<a class="hash-link" href="#confirm-pathogenicity" title="Direct link to heading">#</a></h2><p>Confirmation of the pathogenicity class of a variant may be required in the following cases:</p><ol><li>The automatic variant pathogenicity classification by ACMG was restored after any manipulations with
the criteria on &quot;ACMG Classification&quot; tab;</li><li>Variant annotation or earlier sample analysis stages have been reprocessed;</li><li>The pathogenicity class of the variant was obtained
from <a href="/ngsw-docs-en/settings/custom-annotations#define-annotation-type">the pathogenicity base</a>.</li><li>The pathogenicity class of the variant was stored in the system after
<a href="/ngsw-docs-en/results/main/snvs-indels/pathogenicity#manually-determined-pathogenicity">manual determination of pathogenicity</a>.</li></ol><p>On SNV Viewer page, variants that require pathogenicity confirmation are
indicated by <img src="data:image/png;base64,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" width="18"> next to the pathogenicity button.
If you agree with the variant pathogenicity, click on the bell or the pathogenicity button and
select &quot;Confirm Pathogenicity&quot; option in the dialog:</p><p align="center"><img src="/ngsw-docs-en/assets/images/confirm_pathogenicity-68f96f87811c1be633a961e2bf9e195e.png" width="300"></p><p>On &quot;ACMG Classification&quot; tab, the confirmation warning looks like this:</p><p align="center"><img src="/ngsw-docs-en/assets/images/warning_acmg-94b66642235fd71f7b22d8c65d594133.png" width="900"></p><p>If you agree with the variant pathogenicity,
click on <img src="/ngsw-docs-en/assets/images/validate_pathogenicity-204d087a582668c1f8b325d208472b31.png" width="150">.</p></div></article><nav class="pagination-nav docusaurus-mt-lg" aria-label="Docs pages navigation"><div class="pagination-nav__item"><a class="pagination-nav__link" href="/ngsw-docs-en/results/main/snvs-indels/snv-details-page"><div class="pagination-nav__sublabel">Previous</div><div class="pagination-nav__label">« Variant Details Page</div></a></div><div class="pagination-nav__item pagination-nav__item--next"><a class="pagination-nav__link" href="/ngsw-docs-en/results/main/snvs-indels/onco-relevance"><div class="pagination-nav__sublabel">Next</div><div class="pagination-nav__label">Variant Onco Relevance »</div></a></div></nav></div></div><div class="col col--3"><div class="tableOfContents_35-E thin-scrollbar"><ul class="table-of-contents table-of-contents__left-border"><li><a href="#manually-determined-pathogenicity" class="table-of-contents__link">Manually determined pathogenicity</a></li><li><a href="#acmg-classification" class="table-of-contents__link">Variant ACMG Classification</a><ul><li><a href="#population-data" class="table-of-contents__link">1. Population data</a></li><li><a href="#odds-ratio" class="table-of-contents__link">2. Odds ratio</a></li><li><a href="#uniq-pheno" class="table-of-contents__link">3. Uniq Pheno</a></li><li><a href="#cosegregation" class="table-of-contents__link">4. Cosegregation</a></li><li><a href="#de-novo-variants" class="table-of-contents__link">5. <em>De novo</em> Variants</a></li><li><a href="#cis-trans" class="table-of-contents__link">6. Cis-trans</a></li><li><a href="#in-vitro-or-functional-studies" class="table-of-contents__link">7. <em>In vitro</em> or functional studies</a></li><li><a href="#protein-truncating-variants" class="table-of-contents__link">8. Protein-truncating variants</a></li><li><a href="#missense-variants" class="table-of-contents__link">9. Missense variants</a></li><li><a href="#in-silico-predictions" class="table-of-contents__link">10. <em>In silico</em> predictions</a></li><li><a href="#literature-data" class="table-of-contents__link">11. Literature data</a></li></ul></li><li><a href="#define-pathogenicity-on-acmg-tab" class="table-of-contents__link">Determination of pathogenicity on &quot;ACMG Classification&quot; tab</a></li><li><a href="#define-pathogenicity-by-base" class="table-of-contents__link">Determination of pathogenicity by pathogenicity base</a></li><li><a href="#defined-pathogenicity-in-vv" class="table-of-contents__link">Determined variant pathogenicity in SNV Viewer</a></li><li><a href="#confirm-pathogenicity" class="table-of-contents__link">Confirmation of the variant pathogenicity</a></li></ul></div></div></div></div></main></div></div><footer class="footer footer--dark"><div class="container"><div class="footer__bottom text--center"><div class="footer__copyright">© 2019-2023 Novel Software Systems. All rights reserved.</div></div></div></footer></div>
<script src="/ngsw-docs-en/assets/js/runtime~main.58663b83.js"></script>
<script src="/ngsw-docs-en/assets/js/main.9097e47c.js"></script>
</body>
</html>